When “Low-Grade” Is No Longer Low Risk in IgA Nephropathy
- 16 March 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (4) , 538-540
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A Phase 3 Trial of Atacicept in Patients with IgA NephropathyNew England Journal of Medicine, 2026
- Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialKidney International Reports, 2025
- KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney International, 2025
- Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyKidney International, 2025
- Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyNew England Journal of Medicine, 2025
- Atrasentan in Patients with IgA NephropathyNew England Journal of Medicine, 2025
- Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsKidney International Reports, 2025
- Long-Term Outcomes in IgA NephropathyClinical Journal of the American Society of Nephrology, 2023
- Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialThe Lancet, 2023
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA NephropathyJAMA, 2022